ROLE OF SEROTONINERGIC SYSTEM IN DEVELOPMENT MECHANISMS OF PULMONARY ARTERIAL HYPERTENSION

Pulmonary arterial hypertension in children is considered to be a complex and multifactorial disease, the survival of which depends on timely diagnosis at an early stage of the disease. Pathological changes in pulmonary arterial hypertension are characterized by endothelial hyperplasia, media hypertrophy, adventitious proliferation, obliteration of small arteries, and vasculitis, which leads to rapid death. The exact mechanisms responsible for the pathogenesis of pulmonary hypertension have not yet been elucidated, but the identified endothelial dysfunction is the main initiator of the development of pulmonary hypertension. The cause of this dysfunction is associated with disorders of the serotonergic system. The aim of the work was to study the results of scientific research in different countries of the world on the role of serotonin and its carrier in the pathogenesis of pulmonary arterial hypertension and the possibility of its use in predicting pulmonary arterial hypertension in young children. The results of the study of available scientific literature have shown that a strategy allowing the possibility of early diagnosis of this pathology in children at the present stage does not exist. The study of the role of the serotonergic system is encouraging and promising in addressing this issue.

pulmonary arterial hypertension, early diagnosis, serotonin, membrane serotonin transporter, platelets

1. Авдеев С. Н. Легочная гипертензия. -М.:ГЭОТАР-Медиа, 2015. - 416 с.

2. Бокерия Л. А. Клинические рекомендации по ведению с врожденными пороками сердца. - М.: НЦССХ им А.Н. Бакулева, 2014. -342 с.

3. Бокерия Л. А., Горбачевский С. В., Школьникова М. А. Легочная гипертензия у детей. - М., 2013. - 416 с.

4. Затолокина А. О. Дискуссионные аспекты развития и подходов к терапии синдрома легочной гипертензии у детей с бронхолегочной дисплазией /А. О. Затолокина, Т. В. Белоусова, С. А. Лоскутова //Мать и дитя в Кузбассе. - 2017. - №1(68). - С. 4-10.

5. Клинические рекомендации. Легочная гипертензия у детей. - М.: МЗ РФ, 2017. -60 с.

6. Мустафин A. A. Концентрация серотонина в плазме крови и тромбоцитах, влияние агонистов 5-НТ2 и 5-НТ4 рецепторов на сократимость миокарда у детей с врожденными пороками сердца: Автореф. дис..канд. мед. наук. - Казань, 2008. - 101 с.

7. Мустафин А. А. Серотонин как основная причина развития легочной гипертензии: от гипотезы к лечебной практике /А. А. Мустафин, Р. Р. Нигматулина, Д. Ф. Билалова // Естественные и технические науки. - 2018. -№3 - С. 106-111.

8. Abman S. Pediatric Pulmonary Hypertension. Guidelines from the American Heart Association and American Thoracic Society /S. Abman, G. Hansmann, S. Archer //Circulation. -2015. - V. 132. - P. 2037-2099.

9. Balkovetz D. F. Evidence for an imipramine-sensitive serotonin transporter in human placental brush-border membranes /D. F. Balkovetz, C. Tiruppathi, F. H. Leibach //J. oil. Chem. -1989. - V. 264. - Pp. 2195-2198.

10. Baloira A. Polymorphisms in the Serotonin Transporter Protein (SERT) Gene in Patients With Pulmonary Arterial Hypertension /A. Baloira, M. Nunez, J. Cifrian //Arch. Bronconeumol. -2012. - V. 48, №3. - Pp. 77-80.

11. Belohlavkova S. Fenfluramineinduced pulmonary vasoconstriction: role of serotonin receptors and potassium channels /S. Belohlavkova , J. Simak, A. Kokesova //J. Appl. Physiol. -2001. - V. 91. - Pp. 755-761.

12. Bowers R. Oxidative stress in severe pulmonary hypertension /R. Bowers, C. Cool, R. C. Murphy //Am. J. Respir. Crit. Care Med. -2004. - V. 169. - Pp. 764-769.

13. Castro E. C. C. The Role of Serotonin Transporter in Human Lung Development and in Neonatal Lung Disorders /E. C. C. Castro, P. Sen, W. T. Parks //Canadian Respiratory Journal. -2017. - 10 pages. - Article ID 9064046, https:// doi.org/10.1155/2017/9064046.

14. Chen C. Serotonin drives the activation of pulmonary artery adventitial fibroblasts and TGF-ЬЛ/ Smad3-mediated fibrotic responses through 5-HT2A receptors /C. Chen, X. Han, F. Fan //Mol. Cell. Biochem. - 2014. - V. 397. - Pp. 267-276.

15. Cracowski J. L. Increased lipid peroxidation in patients with pulmonary hypertension /J. L. Cracowski, C. Cracowski, G. Bessard //Am. J. Respir. Crit. Care. Med. - 2001. - V. 164. - Pp. 1038-1042.

16. Eddahibi S. Cross talk between endothelial and smooth muscle cells in pulmonary hypertension - Critical role for serotonin-induced smooth muscle hyperplasia /S. Eddahibi, C. Guignabert, A. M. Barlier-Mur //Circulation. -2006. - V. 113. - Pp. 1857-1864.

17. Fu L. V. Activated platelets contribute to stimulation of cardiac afferents during ischemia in cats: role of 5-HT3 receptors /L. V. Fu, J. S. Longhurst //Physiol. - 2002. - V. 544. - Pp. 897912.

18. Galie N. Guidelines for the diagnosis and treatment of pulmonary hypertension: The task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT) /N. Galie, M. Hoeper, M. Humbert //European heart journal. - 2016. - V. 37. - №1. - P. 67119.

19. Gillis C. N. The fate of circulating amines within the pulmonary circulation /C. N. Gillis, B. R. Pitt //Annu. Rev. physiol. - 1982. - V. 44. - Pp. 269-281.

20. Gray E. A. Assessment of the serotonin pathway as a therapeutic target for pulmonary hypertension /E. A. Gray, H. Tsuchimochi, J.T. Pearson //J. Synchrotron Rad. - 2013. - V. 20. - Pp. 756-764.

21. Guignabert C. Transgenic mice overexpressing the 5-hydroxytryptamine transporter gene in smooth muscle develop pulmonary hypertension /C. Guignabert, M. Izikki, L.I. Tu //Circ. Res. - 2006. - V. 98. - Pp. 1323-1330.

22. Guilluy C. RhoA and Rho kinase activation in human pulmonary hypertension: role of 5-HT signaling /C. Guilluy, S. Eddahibi, C. Agard // Am. J. Respir. Crit. Care Med. - 2009. - V. 179. -Pp. 1151-1158.

23. Hang Z. Association between serotonin transporter (SERT) gene polymorphism and idiopathic pulmonary arterial hypertension: a meta-analysis and review of the literature /Zh. Hang, X. Meng, X. Jia //Metabolism clinical and experimental. - 2013. - V. 62. - Pp. 1867-1875.

24. Harvey G. Citalopram inhibits platelet function independently of SERT mediated 5-HT transport /G. R. Harvey, Y. Ruoling, N. H. Bedwani //Scientific Reports. - 2018. - DOI:10.1038/ s41598-018-21348-3.

25. Herve P. Increased plasma serotonin in primary pulmonary-hypertension /P. Herve, J. M. Launay, M. L. Scrobohaci //Am. J. Med. -1995. - V. 99. - Pp. 249-254.

26. Hood K. Y. Nicotinamide adenine dinucleotide phosphate oxidase-mediated redox signaling and vascular remodeling by 16alpha-hydroxyestrone in human pulmonary artery cells: implications in pulmonary arterial hypertension / K. Y. Hood, A. C. Montezano, A. P. Harvey // Hypertension. - 2016. - V. 68. - Pp. 796-808.

27. Ivy D. D. Paediatric pulmonary hypertension /D. D. Ivy, S. H. Abman, R. J. Barst //J. Am. Coll. Cardiol. - 2013. - V. 62. - Рр. 117-126.

28. Johansen A. K. The serotonin transporter promotes a pathological estrogen metabolic pathway in pulmonary hypertension via cytochrome P450 1B1 /A. K. Johansen, A. Dean, I. Morecroft //Pulmonary Circulation. - 2016. - V. 6, №1. - Pp. 82-92.

29. Kelley L. Biomarkers for pediatric pulmonary arterial hypertension - a call to collaborate Frontiers in Pediatrics //Pediatric Pulmonology. - 2014. - V. 2. - doi: 10.3389/fped.2014. 00007

30. Kramer M. S. Aminorex, dexfenfluramine, and primary pulmonary hypertension /M. S. Kramer, D. A. Lane //J. Clin. Epidemiol. -1998. - V. 51. - Pp. 361-364.

31. Lawrie A. Interdependent serotonin transporter and receptor pathways regulate S100A4/Mts1, a gene associated with pulmonary vascular disease /A. Lawrie, E. Spiekerkoetter, E.C. Martinez //Circ. Res. - 2005. - V. 97. - Pp. 227-235.

32. Lee S. L. Dual effect of serotonin on growth of bovine pulmonary artery smooth muscle cells in culture /S. L. Lee, W. W. Wang, B. J. Moore //Circ. Res. - 1991. - V. 68. - Pp. 13621368.

33. Lee S. L. Superoxide as an intermediate signal for serotonin-induced mitogenesis /S.L. Lee, W. W. Wang, B. L. Fanburg //Free Radic. Biol. Med. - 1998. - V. 24. - Pp. 855-858.

34. Li S. NOX4 regulates ROS levels under normoxic and hypoxic conditions, triggers proliferation, and inhibits apoptosis in pulmonary artery adventitial fibroblasts /S. Li, S. S. Tabar, V. Malec //Antioxid. Redox Signal. - 2008. - V. 10. -Pp. 1687-1697.

35. Liu Y. L. Rho kinase-induced nuclear translocation of ERK1/ERK2 in smooth muscle cell mitogenesis caused by serotonin /Y. L. Liu, Y. J. Suzuki, R. M. Day //Circ. Res. - 2004. - V. 95. -Pp. 579-586.

36. Liu Y. Serotonin-induced growth of pulmonary artery smooth muscle requires activation of phosphatidylinositol 3-kinase/serinethreonine protein kinase B/mammalian target of rapamycin/p70 ribosomal S6 kinase 1 /Y. Liu, B. L. Fanburg //Am. J. Respir. Cell. Mol. Biol. -2006. - V. 34. - Pp. 182-191.

37. Long L. Serotonin increases susceptibility to pulmonary hypertension in BMPR2-deficient mice /L. Long, M. R. MacLean, T. K. Jeffery //Circ. Res. - 2006. - V. 98. - Pp. 818827.

38. Longhurst J. S. Cardiac sympathetic afferent activation provoked by myocardial ischemia and reperfusion. Mechanisms and reflexes /J. S. Longhurst, S. C. Tjen-A-Looi, L. W. Fu //Ann. NY acad. Sci. - 2001. - V. 940. - Pp. 74-95.

39. MacLean M. R. Overexpression of the 5-hydroxytryptamine transporter gene-Effect on pulmonary hemodynamics and hypoxia-induced pulmonary hypertension /M. R. MacLean, G. A. Deuchar, M. N. Hicks //Circulation. - 2004. - V. 109. - Pp. 2150-2155.

40. MacLean M. R. The serotonin hypothesis in pulmonary hypertension revisited: targets for novel therapies (2017 Grover Conference Series) //Pulmonary Circulation. - 2018. - V. 8 (2). - Pp. 1-9.

41. Marcos E. Serotonin transporter inhibitors protect against hypoxic pulmonary hypertension /E. Marcos, S. Adnot, M. H. Pham //Am. J. Respir. Crit. Care Med. - 2003. - V. 168. - Pp. 487-493.

42. Marius M. Definitions and Diagnosis of Pulmonary Hypertension //Journ. Of the American College of Cardiology. - 2013. - V. 62. - Pp. 25.

43. Maurer-Spurej E. The influence of selective serotonin reuptake inhibitors on human platelet serotonin /E. Maurer-Spurej, C. Pittendreigh, K. Solomons //Thromb. Haemost. - 2004. - V. 91 (1). - Pp. 119-128.

44. Penumatsa K. C. Transglutaminase 2-mediated serotonylation in pulmonary hypertension /K. C. Penumatsa, B. L. Fanburg //Am. J. Physiol. Lung Cell Mol. Physiol. - 2014. - V. 306. - Pp. 309-315.

45. Penumatsa K. Tissue transglutaminase promotes serotonin-induced AKT signaling and mitogenesis in pulmonary vascular smooth muscle cells /K. Penumatsa, S. Abualkhair, L. Wei // Cell Signal. - 2014. - V. 26. - Pp. 2818-2825.

46. Ramage A. G. Central cardiovascular regulation and 5-hydroxytryptamine receptors // Brain res. Bull. - 2001. - V. 56. - Pp. 425-439.

47. Ren W. Serotonin transporter interacts with the PDGF receptor in PDGF-BB-induced signaling and mitogenesis in pulmonary artery smooth muscle cells /W. Ren, W. W. Stephanie, L. F. Barry //Am. J. Physiol. Lung Cell Mol. Physiol. - 2011. - V. 300. - Pp. 486-497.

48. Rothman R. B. Aminorex, fenfluramine, and chlorphentermine are serotonin transporter substrates-implications for primary pulmonary hypertension /R. B. Rothman, M. A. Ayestas, C. M. Dersch //Circulation. - 1999. - V. 100. - Pp. 869-875.

49. Rudnick G. Active transport of 5-hydroxytryptamine by plasma membrane vesicles isolated from human blood platelets //J. Biol. Chem. - 1977. - V. 252. - Pp. 2170-2174.

50. Simonneau G. Updateed clinical classification of pulmonary hypertension /G. Simonneau, M. Gatzoulis, I. Adatia //J. Am. Coll. Cardiol. - 2013. - V. 62. - Pp. 34-41.

51. Sturrock A. Transforming growth factor-beta 1 induces Nox4 NAD(P)H oxidase and reactive oxygen species-dependent proliferation in human pulmonary artery smooth muscle cells / A. Sturrock, B. Cahill, K. Norman //Am. J. Physiol. Lung Cell Mol. Physiol. - 2006. - V. 290. - Pp. 661-673.

52. Suzuki Y. J. Activation of GATA-4 by Serotonin in Pulmonary Artery Smooth Muscle Cells /Y. J. Suzuki, R. M. Day, C. C. Tan //J. Biol. Chem. - 2003. - V. 278. - Pp. 17525-17531.

53. Walther D. J. Serotonylation of small GTPases is a signal transduction pathway that triggers platelet alpha-granule release /D. J. Walther, J. U. Peter, S. Winter //Cell. - 2003. - V. 115. - Pp. 851-862.

54. Wedgwood S. ET-1 stimulates pulmonary arterial smooth muscle cell proliferation via induction of reactive oxygen species /S. Wedgwood, R. W. Dettman, S. M. Black //Am. J. Physiol. Lung Cell Mol. Physiol. - 2001. - V. 281. - Pp. 1058-1067.

55. Wong C. M. Reactive oxygen species and antioxidants in pulmonary hypertension /C.M. Wong, G. Bansal, L. Pavlickova //Antioxid. Redox. Signal. - 2013. - V. 18. - Pp. 1789-1796.

56. Yaghini F. A. Angiotensin Iiinduced vascular smooth muscle cell migration and growth are mediated by cytochrome P450 1B1-dependent superoxide generation /F. A. Yaghini, C. Y. Song, E. N. Lavrentyev //Hypertension. -2010. - V. 55. - Pp. 1461-1467.